GlassScriptPhysician profile
Anri Brits
NPI 1336533975
$2,601.90
in general payments reported to CMS, 2019-2025
23 companies · $894 in 2025
The $894 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $69.37 · 2021: $433 · 2022: $181 · 2023: $391 · 2024: $509 · 2025: $894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,725 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,724.82 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $549.69 | 2021-2025 | Qulipta, Ubrelvy |
| Novo Nordisk INC | $326.51 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $242.44 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $234.02 | 2024-2025 | Veozah |
| Lilly USA, LLC | $227.63 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $195.42 | 2019-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $142.84 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $132.21 | 2023-2025 | |
| Exact Sciences Corporation | $127.55 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $65.80 | 2023-2025 | Quviviq, Quviviq |
| Abbott Laboratories | $64.54 | 2023 | Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.92 | 2024-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $44.89 | 2021 | |
| Kaleo, INC. | $28.85 | 2020 | |
| Dynavax Technologies Corporation | $25.44 | 2025 | Heplisav-B |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $23.61 | 2019 | |
| Genentech USA, INC. | $21.48 | 2020 | |
| Sanofi Pasteur INC. | $19.42 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.59 | 2025 | |
| Eisai INC. | $14.99 | 2021 | |
| Tolmar, INC. | $13.67 | 2023 | |
| Biomerieux INC | $13.37 | 2023 | |
| Amneal Pharmaceuticals LLC | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anri Brits listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.